Author

Xiang-Mei Chen

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis

Background Despite optimal renin-angiotensin system (RAS) blockade, patients with diabetic kidney disease (DKD) face substantial residual cardiorenal risk. The 2024 FLOW trial established semaglutide as the first GLP-1 receptor agonist with a dedicated primary renal outcome benefit. We conducted a Bayesian network meta...

Zong-Ze He, Xu Wang, Li Zhang et al. · Frontiers in Pharmacology · 0 citations

Review Oct 2026

Integrated Traditional Chinese and Western Medicine for Immunoglobulin A Nephropathy: Recent Advances and Future Directions.

IgAN is the most common primary glomerular disease worldwide. It is characterized by high heterogeneity and poor long-term prognosis. Integrated traditional Chinese medicine and Western medicine (TCM-WM) has become a distinct and effective strategy for the treatment of IgAN in China. This review summarizes recent evide...

Ying Zheng, Cong-Hui Wang, Xue-Feng Zhou et al. · Seminars in Nephrology · 0 citations